Javed Butler describes the main findings from the Phase IIa CardioCell’s Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic mesenchymal stem cells in patients with non-ischemic cardiomyopathy. He also outlines the main challenges of cardiovascular therapies in cancer patients.